Experimental Medication Found to Significantly Reduce Risk of Heart Attacks and Strokes
A groundbreaking study led by the Cleveland Clinic has uncovered an experimental medication that has the potential to reduce lipoprotein(a) or Lp(a) levels, a cholesterol-like particle that can increase the risk of heart attacks and strokes. Elevated Lp(a) levels are common among Americans, with approximately 64 million individuals in the U.S. and 1.4 billion globally having this condition.
The study, published in The New England Journal of Medicine, revealed that lepodisiran, an experimental drug developed by Eli Lilly, can effectively “silence” the gene responsible for synthesizing Lp(a). This groundbreaking finding could lead to improved treatments for individuals with high Lp(a) levels, as current lifestyle modifications have little impact on this condition.
Lp(a) is a significant risk factor for heart disease, and unlike traditional cholesterol markers, is primarily determined by genetics rather than lifestyle factors. The study participants who received lepodisiran injections showed a near 100% reduction in lipoprotein(a) levels at the one-year mark.
While the study showed promising results, further research is needed to determine if reducing Lp(a) levels can ultimately reduce the risk of heart attacks and strokes. Despite some limitations in the study, including a lack of diversity in participants, the findings suggest a potentially life-changing treatment for millions of individuals at risk of cardiovascular disease.
Overall, this research highlights the potential of gene-based therapies in revolutionizing the treatment of cardiovascular risk factors and improving outcomes for individuals with elevated Lp(a) levels.
————————————————————————
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
————————————————————————
